Serguei Nabirotchkin
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
Journal: Journal of Alzheimer's disease : JAD
Published: July 11, 2022
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis.
Journal: Journal of neuroscience research
Published: February 12, 2020
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Journal: Journal of neuroscience research
Published: February 05, 2020
Next-generation drug repurposing using human genetics and network biology.
Journal: Current opinion in pharmacology
Published: November 28, 2019
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Journal: PloS one
Published: June 15, 2018
Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.
Journal: Journal of neuropathology and experimental neurology
Published: February 07, 2018
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Journal: Orphanet journal of rare diseases
Published: May 16, 2016
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Journal: Scientific reports
Published: February 25, 2015
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Journal: Scientific reports
Published: October 20, 2014
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Journal: Orphanet journal of rare diseases
Published: September 09, 2014
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Journal: Orphanet journal of rare diseases
Published: September 09, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026